Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Merrill Lynch Pharma/Biotech & Medical Device Conference In Brief

This article was originally published in The Gray Sheet

Executive Summary

Exact Sciences driving PreGen-Plus adoption: Grassroots effort by the firm is under way to get its fecal DNA colorectal cancer screening test included in the American Cancer Society's cancer detection guidelines to help drive adoption. The test recorded about $4.9 mil. in 2004 sales. Exact Sciences also has applied for Medicare inclusion and expects a decision within about nine months, President & CEO Don Hardison said during a Feb. 10 presentation at the Merrill Lynch Pharmaceutical, Biotechnology & Medical Device Conference in New York. PreGen-Plus was shown to be four times more effective in identifying invasive cancers than Beckman Coulter's market-leading Hemoccult II fecal occult blood test in a recent study in the New England Journal of Medicine (1"The Gray Sheet" Jan. 3, 2005, p. 18)...

Related Content




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts